"The 'North Tumor Clinical Trial' Mini Program is now online! YIDU TECH (02158) assists in starting a new experience of clinical trial services."

How to make complex clinical trials more "user-friendly" for participants and more "efficient" for managers? With just a few taps, the scheduling of clinical trial visits, reimbursement progress, and medication services can all be easily managed - this is no longer just an idea. Recently, YIDU TECH (02158) and Peking University Cancer Hospital jointly developed a mobile end clinical trial management system (CTMS) - the "Peking Cancer Clinical Trial" mini-program officially launched. This not only embodies the concept of "patient-centered" in practice, but also signifies a comprehensive upgrade in the experience of participants, data security, and operational efficiency in clinical trial management. Experience three major upgrades: making clinical trial participation "worry-free and reassuring" The newly launched CTMS mini-program is based on the experience of trial participants, achieving a breakthrough from "management-oriented" to "service-oriented", deeply integrating into the WeChat ecosystem, and bringing many conveniences to trial participants in the mobile scene: Easier participation. Trial participants do not need to download any apps, they can easily check trial dynamics through the WeChat mini-program: know the visit time, location, and examination items in advance, real-time reimbursement progress, and receive intelligent reminders. In addition, the mini-program seamlessly connects with Peking Cancer's DTP (Direct-to-Patient) system, allowing trial participants to easily access trial-related medication services through a single entry point, greatly reducing participation barriers and providing a more thoughtful service experience. Safer communication. Key communications are conducted through official enterprise WeChat channels, critical medical data such as test reports and trial protocols are encrypted and transmitted through the CTMS platform, ensuring data security and avoiding the risk of circulation through unofficial channels. More consistent experience. With the help of WeChat's built-in functions, when there are changes in CRC personnel, previous communication records and project information will be seamlessly transferred, avoiding problems such as repetitive communication and information disconnection for trial participants, ensuring smooth and consistent trial processes, reducing the burden and communication costs for trial participants. This series of improvements focusing on participants signifies the successful extension of the digitization of clinical trials from an emphasis on internal process management of institutions to considering the service experience for external participants. This mini-program also significantly improves the efficiency of CRC. It breaks the limitations of office settings, synchronizes tasks from the PC end to the mobile end, allowing tasks to be handled anytime, anywhere. It also supports core operations such as adding trial participant information and modifying trial participant status, reducing the limitations of fixed venues and devices in the past, making work arrangements more flexible and efficient. With continuous iterative upgrades to the system, it will expand applications in more innovative scenarios such as remote electronic informed consent and rapid reading of Adverse Events (AE) on the mobile end. Visible efficiency: CTMS helps significantly shorten the average project initiation time Since Peking Cancer fully implemented the YIDU TECH CTMS system in 2019, the two sides have continued to promote the evolution of the "Internet + Clinical Trial Management" ecosystem. The cooperation between the two parties covers multiple core scenarios from data governance to clinical research: the medical data intelligence platform assisted by YIDU TECH provides a strong data insight foundation for scientific research and clinical activities; the joint construction of multiple disease databases represented by the gastric cancer specialty library promotes the standardized exploration of diagnosis and treatment norms; the jointly developed and implemented MDT platform and research ward platform comprehensively enhance multidisciplinary collaboration and the overall efficiency of clinical research. Built on this solid and extensive cooperation foundation, the CTMS clinical research management system, as a GCP-standardized end-to-end digital management platform, provides Peking Cancer with a one-stop solution from project initiation, execution to completion. Its value has been fully validated in practice: through process standardization and detailed control throughout the cycle, the average project initiation time for Peking Cancer clinical trial projects has been significantly shortened, surpassing industry average efficiency levels. The launch of the mobile end is a further improvement on the efficient management foundation to enhance participant services, achieving a double enhancement of management efficiency and patient experience. Proven and promotable, YIDU TECH's CTMS system empowers more than 60 hospitals nationwide The cooperation achievements with Peking Cancer are an example of the value of YIDU TECH's CTMS system. As an important innovative achievement released by YIDU TECH at the 2025 Service Trade Fair, its reliability, professionalism, and universality have been widely recognized. It has been successfully applied in more than 60 well-known hospitals across the country, supporting the efficient conduct of various complex clinical trials. CTMS is not only a management tool for trial institutions, but also a key link embedded in the "drug discovery - preclinical research - clinical trials - market approval" full R&D chain, promoting the intelligent transformation and overall efficiency improvement of pharmaceutical research and development. In the future, YIDU TECH will continue to leverage its core technological advantages in the medical intelligence field, promoting quality technology and services to benefit more medical institutions, researchers, and trial participants, effectively improving clinical research efficiency and helping safe and effective therapies reach patients faster.